Raj Patil, Ph.D. Email & Phone Number

Responsible for developing OKYO’s scientific strategy to build a diverse pipeline of novel products targeting ocular disorders and oversee non-clinical and clinical development of lead drug candidates by building partnerships and collaborations with academia and various CROs and CDMOs in order to achieve rapid clinical translation, with a path to registration.Provide visionary and scientific leadership, aligning scientific expectations with the corporate vision and interacting with academic KOLs, investigators and other clinical stakeholders.Represent OKYO and its programs to internal and external audiences, including the Board of Directors, SAB, investment groups, medical and regulatory communities, as well as pharmaceutical/biotechnology industry collaborators/partners.

Andover, Massachusetts, Us

Accountable for the global planning, execution, and management of Ora’s R&D Institute.About Ora, Inc.Ora (Ophthalmic Research Associates) is a leading full-service preclinical and clinical ophthalmic drug and device development firm. Over 40 years of global experience has given Ora unparalleled insight into clinical strategy and regulatory requirements, all tailored to meet your study specific needs.

OKYO Pharma (LSE: OKYO) is a biotechnology company developing first-in-class drug candidates for treatment of sight-threatening eye diseases and non-opioid analgesics.

Salt Lake City, Ut, Us

Existing therapies rely on drops or injections to deliver medicine, and often do not reach the retina or the inside of cells. iVeena uses novel approaches — including drug delivery from the lens capsule, minimally invasive implants, and intracellular therapy — to reach target tissues for better patient outcomes.

Singapore, Singapore, Sg

Dept of Ophthalmology & Visual Sciences Academic Clinical ProgramEngaged in integrating the clinical and discovery expertise to create a unique platform for biomarker/target identification and drug repurposing for retinal diseases in partnership with pharmaceutical industries.

Basel, Baselstadt, Ch

Identified novel preclinical targets for retinal diseases and established project teams to identify lead candidates. Managed and allocated resources needed to achieve group objectives including budgeting and capital expenses and implemented required technologies. Led and collaborated with multidisciplinary project teams of in vitro/in vivo biologists, medicinal chemists and DMPK scientists. Presented periodic briefings/status updates and technical data to senior executives, project leaders, and external collaborators.

Geneva, Switzerland, Ch

Managed and executed several academic/industry biomedical research collaborations. Led a team of 6-8 scientists (PhD, MS, BS) focused on advancing the preclinical candidates (small molecules, siRNA and biologics) to clinical development. Established in vitro and in vivo models, and evaluated preclinical candidates. Executed planning, organizing and directing resources (both personnel and technologies) for multiple discovery projects in the therapeutic areas of glaucoma, retina and allergy and inflammation programs. Developed novel technologies and successfully transferred the technology to CROs and academic collaborators for the advancement of Drug Discovery Projects.

Omaha, Nebraska, Us

Dept of Ophthalmology & Visual SciencesResearch Interest: Glaucoma, AMD and Diabetic Retinopathy

St. Louis, Mo, Us

Dept of Ophthalmology & Visual SciencesResearch Interest: Glaucoma, Retina, Pharmacology, Physiology

Postdoctoral Scholar, Biochemistry And Molecular Biology

Doctor Of Philosophy - Phd, Biochemistry